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Abstract As part of the Seattle Structural Genomics
Center for Infectious Disease, we seek to enhance structural
genomics with ligand-bound structure data which can serve
as a blueprint for structure-based drug design. We have
adapted fragment-based screening methods to our structural
genomics pipeline to generate multiple ligand-bound struc-
tures of high priority drug targets from pathogenic organ-
isms. In this study, we report fragment screening methods
and structure determination results for 2C-methyl-D-eryth-
ritol-2,4-cyclo-diphosphate (MECP) synthase from Burk-
holderia pseudomallei, the gram-negative bacterium which
causes melioidosis. Screening by nuclear magnetic
resonance spectroscopy as well as crystal soaking followed
by X-ray diffraction led to the identiﬁcation of several small
molecules which bind this enzyme in a critical metabolic
pathway. A series of complex structures obtained with
screening hits reveal distinct binding pockets and a range of
small molecules which form complexes with the target.
Additional soaks with these compounds further demonstrate
asubsetoffragmentstoonlybindtheproteinwhenpresentin
speciﬁc combinations. This ensemble of fragment-bound
complexes illuminates several characteristics of MECP
synthase, including a previously unknown binding surface
external to the catalytic active site. These ligand-bound
structures now serve to guide medicinal chemists and
structural biologists in rational designof novel inhibitors for
this enzyme.
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Introduction
The mission of the Seattle Structural Genomics Center for
Infectious Disease (SSGCID) is to supply the scientiﬁc
community with structural information that can facilitate
structure-based design of new chemotherapeutics to
combat pathogenic organisms [1, 2]. As of this writing,
our gene-to-structure pipeline has generated nearly 300
protein structures from Category A, B and C microbial
organisms designated by the National Institute of Allergy
and Infectious Disease (NIAID). The SSGCID directs
effort to obtain ligand-bound structures for select high-
value targets, for which we have adapted fragment-based
screening methods to our structural genomics pipeline.
Fragment screening with a diverse, metabolite-based
compound library allows both the testing of proven and
the discovery of new chemical moieties which bind to a
protein [3–6]. The size and reduced complexity of typical
fragment molecules (B300 Da) allow for a diverse sam-
pling of chemical space with a compound library small
enough (*1,500 compounds) for practical applications in
crystallographic screening [7–10]. With adequate sam-
pling of the natural metabolome, a single, all-purpose
fragment library can retrieve small molecule binders for
protein targets from a diverse array of infectious disease
organisms.
In this study, we describe fragment screening methods
using our Fragments of Life
TM (FOL) library to generate
co-crystal structures for an infectious disease drug target
from Burkholderia pseudomallei (Bp). We conducted
fragment screens with 2C-methyl-D-erythritol 2,4-cyclod-
iphosphate (MECP) synthase from B. pseudomallei
(BpIspF) using nuclear magnetic resonance (NMR) spec-
troscopy and X-ray crystallography. This bacterium causes
melioidosis, a disease with a current mortality rate of
20–50% which require months-long antibiotic regiments to
clear the host system [11]. These factors, along with the
ability of B. pseudomallei to frequently evade immune
response, has led to its designation as an emerging
pathogen and a potential bioterrorism agent by the
NIAID[12–14]. MECP synthase is part of the methyl-
erythritol isoprenoid (MEP) biosynthetic pathway, an
alternative metabolic pathway for isoprene synthesis not
present in humans [15, 16]. Previous studies have shown
the MEP pathway to be essential for certain bacteria as well
as species of Plasmodium and other protozoans, with
clinical efﬁcacy demonstrated for drugs targeting the IspC
enzyme, upstream of MECP synthase (IspF) in the pathway
[16–21]. Ongoing gene deletion studies with B. pseudo-
mallei and B. thailandensis indicate a likelihood that every
non-duplicated gene product from the MEP pathway is
essential for bacterial growth [22]. Using an iterative
fragment-based approach to screening followed by com-
plex structure determination, we have deposited over a
dozen ligand-bound structures of MECP synthase. This
ensemble of ligand-bound complexes now serves to guide
medicinal chemists and other researchers in developing
novel antibacterial agents to treat B. pseudomallei infection
and other pathogenic organisms for which the MEP path-
way is essential.
Materials and methods
Protein expression and puriﬁcation
2C-methyl-D-erythritol-2,4-cyclodiphosphate synthase (E.C.
4.6.1.12) from Burkholderia pseudomallei (BpIspF; target
database ID: BupsA.00122.a) was expressed in E. coli using
BL21(DE3)R3 Rosetta cells and autoinduction media in a
LEX bioreactor. Starter cultures of lysogeny broth with
appropriate antibiotics were grown for *18 h at 37C.
Antibiotics were added to 2 L bottles of sterile ZYP-5052
auto-induction media and the bottles inoculated with over-
nightcultures.InoculatedbottleswerethenplacedintoaLEX
bioreactor and cultures grown for *24 h at 25C. The tem-
peraturewasthenreducedto15Candgrownforanadditional
*60 h. To harvest, the media was centrifuged at 4,000 RCF
for 20 min at 4C. Cell paste was ﬂash frozen in liquid
nitrogen and stored at -80C prior to puriﬁcation. Frozen
cells were re-suspended in lysis buffer (25 mM HEPES (pH
7.0), 500 mM NaCl, 5% (v/v) glycerol, 30 mM imidazole,
0.025% (w/v) sodium azide, 0.5% (w/v) CHAPS, 10 mM
MgCl2, 1 mM TCEP, 250 ng/mL AEBSF, and 0.05 lg/mL
lysozyme) and disrupted on ice for 30 min with a Virtis
sonicator using alternating on/off cycles of 15 s. Cell debris
was incubated with 20 lL of Benzonase nuclease (25 U/mL)
at room temperature for 45 min, and clariﬁed by centrifu-
gation on a Sorvall SLA-1500 at 29,700 RCF for 75 min
at 4C.
Protein for X-ray crystallography was puriﬁed from
clariﬁed cell lysate by immobilized metal afﬁnity chro-
matography. We used a His Trap FF 5 mL column (GE
Healthcare) equilibrated with binding buffer (25 mM
HEPES (pH 7.0), 500 mM NaCl, 5% (v/v) glycerol,
30 mM imidazole, 0.025% (w/v) sodium azide, 1 mM
TCEP). The protein was eluted in the same buffer with
250 mM imidazole added. Size exclusion chromatography
(SEC) was done using a HiLoad 26/60 Superdex 75 column
(GE Healthcare) equilibrated in SEC buffer (20 mM
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glycerol). Pure fractions were collected and pooled from a
single peak in the chromatogram, and concentrated using
Amicon Ultra centrifugal ﬁlters. The ﬁnal protein was
concentrated to approximately 27 mg/mL, aliquoted into
100 lL tubes, ﬂash frozen in liquid nitrogen and stored at
-80C.
Protein for NMR spectroscopy was puriﬁed using the
above protocol but with removal of the afﬁnity tag by
incubation with His-tagged 3C protease. This was done
after the ﬁrst His Trap column puriﬁcation, and was fol-
lowed by gravity-ﬂow puriﬁcation on a Ni–NTA packed
column to remove the tag, the 3C protease, and any unc-
leaved BpIspF. The tagless protein was collected in the
ﬂow-through and further resolved using the same SEC
puriﬁcation method as the ﬁrst batch. The protein was
concentrated using Amicon Ultra ﬁlters to approximately
30 mg/mL, aliquoted into 100 lL tubes, ﬂash-frozen in
liquid nitrogen and stored at -80C.
Crystallization and fragment screening by x-ray
crystallography
Robust, well-diffracting crystals of BpIspF protein were
grown by sitting drop vapor diffusion over 1–2 days in
trays incubated at 16C. Drops for initial crystal formation
of the uncleaved protein contain 0.5 lL protein solution
(20 mg/mL of BpIspF in SEC buffer) mixed with 0.5 lL
crystallization buffer (200 mM NaCl, 100 mM Tris–HCl
(pH = 8.0), 20% (w/v) PEG 4000, 5 mM ZnCl2), with
reservoirs containing 80 lL of crystallization buffer.
Fragment soaking trays were prepared by adding 1.0 lL
methanol drops containing up to 8 fragments at 6.25 mM
each to individual crystal tray wells, and allowed to
evaporate to dry ﬁlm. Compounds were then resuspended
in 1.0 lL crystallization buffer, and 2 or 3 apo crystals
transferred to each well, with 20 lL of crystallization
buffer added to the reservoir [3]. Preliminary testing with
several cytosine derivatives indicated that up to 3 weeks of
soak time is necessary to obtain bound ligands with sufﬁ-
cient occupancy for structure determination. Therefore,
crystals of BpIspF were allowed to soak in primary FOL
mixture pools for approximately 3 weeks prior to har-
vesting and data collection. Cryo-protectant solutions were
prepared by resuspending dry ﬁlm fragment pools in drops
consisting of 0.3 lL ethylene glycol and 0.7 lL crystalli-
zation buffer. To deconvolute fragment mixtures and
conﬁrm small molecule identity, individual follow-up
soaks were conducted in the same manner with individual
fragments at 25 mM in the soak drop. Focused soaking
trials with pools and individual molecules identiﬁed from
NMR-based fragment screening were conducted in the
same manner, with fragments at 10–25 mM in the soak
drop.
Fragment screening by NMR spectroscopy
NMRsampleswerepreparedbydilutingtagless,concentrated
BpIspF protein in SEC buffer to 20 lM( 6 0lMm o n o m e r )
with NMR buffer (10 mM K-Phos (pH 7.8), 50 mM NaCl,
10% (v/v)
2H2O). Fragment pools were assayed at ligand
concentrations of 400 lM, with 400 lMc y t i d i n ea n d2 0lL
deuterated dimethyl sulfoxide (d6-DMSO) present in a
500 lLsamplevolume.Allexperimentswereconductedona
600-MHz Bruker AVspectrometerwithTCIcryoprobe setto
280 K. Screening was done using ligand-observe, proton-
based one-dimensional saturation transfer difference nuclear
magnetic resonance (STD-NMR) [23] and two-dimensional
nuclear Overhauser effect spectroscopy (NOESY) [24],
according to previously published methods [25]. Brieﬂy, 32
scans and 32,000 points were acquired over a 14 ppm sweep
width for STD-NMR data, with a total recycle delay of 4.0 s
for each mixture. A low-power 30-ms spin-lock pulse was
added to ﬁlter out low-level protein peaks, and a WATER-
GATE sequence added to suppress bulk water signal [26].
STD-NMRpre-saturationwasdoneusinga3.0 s-longtrainof
Gaussian-shaped pulses with a spectral width of 600 Hz
focused at -1.0 ppm, with reference irradiation set to
30 ppm. For NOESY experiments, 2,048 9 160 points were
collectedwithamixingtimeof500 msandarecycledelayof
2.0 s, with WATERGATE solvent suppression for each
mixture. A total of 390 compounds in a dozen mixtures were
tested;typicaldatafromNMRscreeningisshownforMixture
#8 (Fig. 1).
Structure determination by X-ray crystallography
The apo structure of BpIspF (PDB ID: 3F0D) was collected
on beamline 23-ID-D at the Argonne National Laboratory.
The 12 ligand-bound complexes discussed in this work
(PDB IDs: 3F0G, 3IEQ, 3IEW, 3IKE, 3IKF, 3JVH, 3K14,
3K2X, 3MBM, 3P0Z, 3P10 and 3QHD) were collected in-
house using a Rigaku SuperBright FR-E ? X-ray genera-
tor with Osmic VariMax HF optics and a Saturn 944?
CCD detector. Diffraction data were reduced and scaled
either with HKL2000 [27] or XDS/XSCALE [28]. Each
structure was solved by molecular replacement and rigid
body reﬁnement using pre-existing structures of IspF
(Table 1). Small molecule structures were built manually
using Sketcher, and ligand–protein complex models reﬁned
using REFMAC5 [29], both part of the CCP4 program
suite [30]. Reﬁnement included TLS parameters with up to
8 TLS groups per chain in each monomer[31]. Final
Fragment screening for SSGCID drug targets 65
123structures were obtained after numerous rounds of REF-
MAC5 [29] reﬁnement and manual model-building using
the Crystallographic Object-Oriented Toolkit (Coot) [32].
Each structure was evaluated using the MolProbity web-
server [33] and internally peer reviewed, prior to validation
and deposition with the Protein Data Bank [34, 35]. Dif-
fraction data and reﬁnement statistics for each structure are
listed below (Table 1).
Results and discussion
Primary fragment screening of BpIspF by X-Ray
crystallography
Fragment screening by X-ray crystallography has the
advantage of obtaining structural data on the complex
directly from screening efforts [3, 36, 37]. Preliminary
Fig. 1 a STD-NMR and 2D NOESY spectra with b zoomed-in
region for a sample containing BpIspF, cytidine and 34 small
molecule fragments from primary screening. Peaks visible in the STD
spectrum (purple) and positive crosspeaks (red) generated by negative
NOE signals are indicative of small molecule binders. c Chemical
structures for all compounds in this mixture; binders are boxed and
labeled, including FOL535 which was previously observed to bind
BpIspF by X-ray crystallography (PDB: 3K14). Figure generated
using iNMR software (http://www.inmr.net)
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123crystallographic trials with BpIspF revealed this enzyme
capable of forming relatively large, solid crystals of the
stable trimeric holoenzyme which did not dissolve under
fragment soaking conditions. The BpIspF protein used for
all crystallographic experiments retains a histidine-based
afﬁnity tag which was not visible by X-ray diffraction, and
does not appear to interfere with ligand binding by X-ray or
NMR analysis. We therefore conducted a fragment screen
of BpIspF with our Fragments of Life
TM (FOL) library [3]
by X-ray crystallography, exposing the target to approxi-
mately 1,500 different small molecules. To conduct the
screen, pre-formed apo crystals of BpIspF were soaked in
pools containing up to 8 different small molecules resus-
pended in crystallization buffer (see ‘‘Methods’’) [3, 38].
Observing electron density for bound small molecules
requires high concentrations, due to the relatively weak-
binding afﬁnity of most fragment-sized molecules, and the
high concentration of protein (and active sites) present in
the crystal [3, 36, 37]. Preliminary time-course experiments
with BpIspF further indicated that 2–3 weeks was some-
times necessary to observe zinc-coordinated fragments in
the active site, even with high (25 mM) concentrations of
ligand added (data not shown). This is likely due to com-
petition with a thermodynamically stable water molecule
bound to the catalytic coordination site of the metal ion.
Therefore, crystals were allowed to soak for at least
3 weeks per FOL mixture, to provide sufﬁcient time for
high occupancy of fragments in the crystal.
Diffraction analysis of BpIspF crystals soaked in FOL
pools resulted in two distinct categories of fragment hits
(Fig. 2). One set consisted entirely of cytosine derivatives
which recapitulate the cytidylyl moiety of the native
substrate while bound (Fig. 3)[ 39]. Uracil, thymine, and
other pyrimidine nucleotide analogs contained within the
FOL library were not recovered from crystal soaking
experiments, demonstrating the speciﬁcity of cytosine
binding for this sub-pocket. A second set of FOL hits
comprised a variable series of heteroaromatic compounds
which bound in an adjacent sub-pocket of the active site.
The main mode of binding for these fragments is through
heteroaromatic nitrogen coordination to the catalytic zinc
ion of the protein (Fig. 3). No other sites on the trimeric
holoenzyme were observed to bind fragments from pri-
mary screening by X-ray crystallography. Molecules of
Tris, glycerol, and acetate appear along the threefold axis
of the trimeric protein in some BpIspF structures (Fig. 4),
but no FOL molecules were observed to bind in this
region. Altogether, structures of 6 unique cytosine deriv-
atives and 3 different zinc-binding ligands were recovered
from a single FOL library screen by X-ray crystallogra-
phy (Table 1). Furthermore, these ligands appear to
bind all three active sites in their respective crystal
structures, resulting in a 3:1 ligand:homotrimer binding
stoichiometry (Table 1). Some differences between active
sites have been observed, suggestive of phosphate
hydrolysis in the crystal (see PDB ID:3IEW). This is
likely due to low-level activity of BpIspF, whose native
function includes metal-activated cleavage of a phospho-
diester bond [15, 39]. Nevertheless, the three active sites
of a given homotrimer appear fully occupied by each
fragment hit identiﬁed from primary screening by FOL
soaks and X-ray diffraction.
Fig. 2 Chemical structures and PDB codes for a cytosine pocket,
b zinc-site, and c external site BpIspF-binding fragments
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In searching for additional fragment binders to complement
our BpIspF structure ensemble, we applied NMR spec-
troscopy to screen a subset of the FOL library. Fragment
screening by NMR spectroscopy can quickly distinguish
binding from non-binding ligands in solution, and is often
used for initial screens prior to crystallographic efforts [40–
42]. Preliminary studies showed BpIspF to remain a stable
trimer in low-salt buffer and amenable to ligand-observe
NMR-based screening. We therefore screened a druglike
set of 390 compounds contained within the FOL library by
preparing twelve samples of BpIspF, each containing
cytidine and 30–40 compounds (see ‘‘Methods’’). Cytidine
was added to speciﬁcally probe for inter-ligand NOE sig-
nals (ILOEs) [24, 43] between itself and fragments with
afﬁnity for the adjacent binding site. Fragments were
selected which did not contain a cytosine ring structure, so
as not to compete for the cytidine pocket in solution.
Unfortunately, no ILOE signals were detected in the
NOESY spectra, perhaps because of too few non-
exchangeable proton resonances close to the zinc-binding
site to serve as ILOE probes. Nevertheless, fragment
screening by NMR spectroscopy led to the identiﬁcation of
61 putative hits for BpIspF by STD-NMR, of which 56
were also observed to bind by transfer NOESY.
Among the hits identiﬁed from NMR screening were
FOL535 and FOL717, ligands previously known to bind
BpIspF through crystallographic fragment screening
(PDB:3K14 and 3IKF, respectively). However, none of the
remaining hits had been detected through primary screen-
ing by crystal soaking and X-ray diffraction, even though
they were all part of the original FOL library. The size,
shape and chemical properties of these NMR hits covered a
slightly larger chemical space than the fragments discov-
ered through direct crystal soaking experiments. However,
the majority NMR hits were equally small and chemically
quite similar to the FOL compounds discovered by X-ray
crystallography, suggesting nothing to make them incapa-
ble of binding to BpIspF crystals. A separate analysis
demonstrated no particular trend in crystal contacts or
solvent channel diameters for the apo crystal of BpIspF
which would prevent any fragment-sized molecule from
binding [44]. Since we did not acquire speciﬁcity data
during primary screening, it is possible that some of the
NMR hits were non-speciﬁc binders, and thus would never
appear bound to a protein crystal by X-ray diffraction. It is
also possible that the NMR hits bind BpIspF too weakly to
obtain sufﬁcient occupancy for X-ray diffraction experi-
ments. We therefore conducted additional soaks at higher
concentrations with our NMR hits, to see if this would lead
to new fragments and additional complex structures.
Fig. 3 Small molecules which
bind BpIspF fall into three
distinct categories: a cytidine
pocket binders, including
cytosine (yellow), cytidine
(cyan), 50-iodo-cytidine (green),
CMP (navy), CDP (magenta)
and CTP (white); b zinc-site
binders FOL535 (magenta),
FOL717 (navy), FOL8395
(cyan) and FOL955 (white); and
c external site binders FOL694
(magenta) and FOL795 (cyan).
A single protein crystal
structure (PDB ID: 3P10) is
depicted for clarity. Key
interactions illustrated in
a between cytidine, D48 of one
monomer, and A102, P105 and
A108 of the opposite monomer
(black dashes). Cytidine and
FOL955 (white) are illustrated
in the active site for c. Figure
generated using PyMol [57]
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123Follow-up crystal trials with NMR-based fragment hits
Ligand-observe NMR data on primary screening mixtures
cannot distinguish speciﬁc from non-speciﬁc binders
without competitive titration or other follow-up experi-
ments [45–47]. Since our main goal was the generation of
new complex structures, we immediately employed these
putative NMR hits into crystal soaks without ﬁrst con-
ﬁrming their binding site speciﬁcity (or lack thereof) with
additional experiments. All 61 NMR hits (including
FOL535 and FOL717) were grouped into pools of 4–5
compounds based on shape dissimilarity and dissolved in
drops to 10 and 25 mM for crystal soaking trials. The same
pools were used in parallel soaks with either cytosine or
cytidine added to replicate in some manner the conditions
used for NMR screening. The soak time was also increased
to give weakly-binding zinc-site fragments more time to
displace the coordinated water molecule. After 4–8 weeks,
none of the NMR hits soaked in the absence of cytosine or
cytidine resulted in complex BpIspF structures, with the
exception of FOL535 and FOL717. From the pools con-
taining cytosine, only FOL717 appeared to possess high
enough afﬁnity and occupancy to generate a reasonable
dataset for structure determination (PDB: 3MBM). How-
ever, pools containing NMR fragment hits and cytidine
generated density for 3 new fragments which had not
previously been observed to bind by X-ray crystallography
(Fig. 3). Two of these (FOL694 and FOL795) appear to
bind a hydrophobic region external to the active site in an
often disordered loop above the catalytic zinc ion (PDBs:
3P10 and 3QHD). The third (FOL955) binds within the
active site and coordinates to the catalytic zinc ion with an
aromatic nitrogen, in a manner similar to that of other zinc-
binding fragments (PDB: 3P0Z).
The identity of all 3 NMR-derived fragment hits have
been conﬁrmed by individual soaks of BpIspF crystals with
cytidine, and exhibit a cytidine dependence for binding.
Repeated attempts to soak these fragments with BpIspF
crystals, either alone or in the presence of cytosine, failed
to generate high-resolution complex data. Thus the binding
of cytidine to pre-formed apo crystals of BpIspF appears to
enhance the afﬁnities of these other small molecules for the
target. The native substrate of IspF branches across the
BpIspF active site, making key interactions to residues on
both monomers [39]. Some of these interactions are con-
served when cytidine (but not cytosine) is bound, forming
hydrogen bonds which mimic that of the substrate-bound
conformation. The 4-amino protons and carbonyl oxygen
of cytidine contact the backbone of one monomer at A102,
P105 and A108, while the 20- and 30-ribosyl hydroxyls
make contact with the D58 side chain of the other mono-
mer (Fig. 3). This provides a structural basis for cytidine
causing an increase in the structural integrity of the active
site, hence the dependency of certain fragments on its
presence for binding to BpIspF.
In addition to their dependence on cytidine, another
unique aspect of the NMR-based hits is their binding stoi-
chiometry. Unlike all of the hits obtained directly through
crystal soaking, FOL694, FOL795 and FOL955 were only
observed in one active site per homotrimer of BpIspF
(Table 1). Repeat experiments show this to be the case for
multiple crystal trials, as it was for FOL717 and FOL535 in
binding all three active sites (data not shown). In most
BpIspF structures bound to fragments, the loop which
generates the binding site for FOL694 and FOL795 is too
disordered to properly model, suggestive of a high degree of
ﬂexibility in this region. However, this does not explain the
1:3 stoichiometry of FOL955, which only binds to a single
active site of homotrimeric BpIspF, in a structure with three
clearly-deﬁned pockets. In all of our BpIspF structures, the
active site appears solvent accessible, and crystal contacts
do not occlude any one active site more than the other two
[44]. One possible explanation is differential afﬁnity across
the three active sites in the crystal form used for soaking.
None of the crystals in our ensemble display perfect
threefold crystallographic symmetry along the trimer
Fig. 4 Structure ensemble of fragments bound to 2C-methyl-D-
erythritol-2,4-cyclo-diphosphate synthase from Burkholderia pseudo-
mallei (PDB IDs 3IEQ, 3IEW, 3IKE, 3IKF, 3JVH, 3K14, 3K2X,
3MBM, 3P0Z, 3P10 and 3QHD). The holoenzyme possesses three
active sites, located in a solvent-exposed groove along each
monomer–monomer interface (green, cyan, magenta). Each active
site also contains a catalytic zinc ion (yellow spheres). Molecules of
tris, glycerol, and acetate were observed to bind in the center of the
trimeric protein, but no FOL compounds were found in this site. For
clarity, a single protein crystal structure (PDB ID:3P10) is viewed
along the threefold trimer axis. Figure generated using PyMol [57]
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123interface, making each monomer (and each active site)
slightly different. However, the presence of 2Fo–Fc density
near the catalytic zinc ion in each active site of these
structures suggest that 3:1 binding does occur, but without
sufﬁcient density to model fragments into all three active
sites. Future studies with close chemical variants of these
fragments and solution-state binding afﬁnity measurements
will hopefully shed additional light on the underlying cau-
ses for this asymmetric binding stoichiometry.
Conclusion
In searching for ways to rapidly generate multiple ligand-
boundstructuresforagiventarget,wehave foundfragment-
based screening offers a variety of solutions. Biophysical
methods such as ligand-observe NMR spectroscopy and
X-ray crystallography are broadly applicable to macromo-
lecular targets with minimal target-speciﬁc requirements,
and are therefore well-suited to a high throughput pipeline.
We propose that our compound library derived from the
natural metabolome will maximize chances for complexa-
tion with disparate targets, while minimizing the need for
target-speciﬁc ﬁne-tuning over the course of many fragment
screening campaigns. In conducting our studies on BpIspF,
small molecules which were not observed by one screening
method were found by another. This outcome underlines the
importance of implementing two or more orthogonal
methods in fragment-based screening to identify and verify
hits as well as increase the potential pool of candidates [40].
Results from this study further revealed the inﬂuence one
fragment can have on the binding afﬁnity of another for a
static target in crystal form. With strategic preparation of
focused fragment mixtures for secondary experiments, the
effect one fragment has on another can be exploited to
generate ternary and even higher-order complexes.
The wealth of ligand-binding data generated by this
approach now serves as a starting point for structure-based
drug design. Using structural information on fragment-
bound structures to chemically elaborate hits into more
potent molecules has previously been demonstrated in our
laboratory [3, 48] and elsewhere in the literature [49–54].
In collaboration with medicinal chemists outside the
SSGCID, we are pursuing a similar approach with BpIspF
and other enzymes from the MEP pathway, using our
ensemble of fragment-bound complexes as an initial
blueprint. With the pipeline for new antibacterial drugs and
other medicines dwindling, there will be increased pressure
to develop novel antimicrobials in the coming years to
combat drug-resistant strains and other emerging threats to
human health [55, 56]. Fragment-based screening coupled
with structure-based drug design is a tandem approach
which can rapidly generate novel leads for both known and
novel biologically relevant targets. We have demonstrated
one target from the SSGCID to be amenable to biophysical
fragment screening, and are now reﬁning these methods to
increase our fragment screening throughput. We intend to
generate similar structure ensembles for other MEP targets,
from B. pseudomallei and a variety of pathogenic organ-
isms as part of our structural genomics efforts.
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